BioCentury | Feb 28, 2019
Translation in Brief

Damming up metastasis

...also said the decoys lack the bleeding risks associated with approved antiplatelet therapies such as abciximab...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

...CD41/CD61) inhibitors Integrilin and Aggrastat tirofiban and Johnson & Johnson markets the CD41/CD61 mAb ReoPro abciximab...
BioCentury | Nov 21, 2013
Targets & Mechanisms

Riding the integrin wave in thrombosis

...Indeed, there are three inhibitors on the market: Johnson & Johnson markets the mAb ReoPro abciximab...
BioCentury | Apr 2, 2012
Clinical News

ReoPro abciximab: Postmarketing study data

...infarction (STEMI) undergoing percutaneous coronary intervention (PCI) showed that a 0.25 mg/kg bolus of intracoronary ReoPro...
...15.1% vs. 17.9%, p=0.03) and median absolute infarct mass vs. patients who did not receive ReoPro...
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ReoPro abciximab...
BioCentury | Jan 2, 2012
Clinical News

ReoPro abciximab: Phase IV data

...trial in 1,721 patients with acute with non-ST-segment-elevation myocardial infarction (NSTEMI) undergoing PCI showing that ReoPro...
...MI, urgent TVR and major bleeding at 30 days vs. bivalirudin (10.9% vs. 11%, p=0.94). ReoPro...
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ReoPro abciximab...
BioCentury | Nov 14, 2011
Clinical News

ALX-0081: Development discontinued

...all bleeding events according to TIMI criteria within 30 days of treatment compared to ReoPro abciximab...
...in bleeding events with ALX-0081 vs. ReoPro. Additionally, 3 and 2 patients receiving ALX-0081 and ReoPro...
...end of 2013. ALX-0081 has Orphan Drug designation in the U.S. and EU for TTP. ReoPro...
BioCentury | Nov 11, 2011
Clinical News

ALX-0081 misses in ACS, continuing in TTP

...a composite rate of all bleeding events within 30 days of treatment compared to ReoPro abciximab...
...expected by year end 2013. Ablynx was off EUR 0.02 to EUR 2.69 on Thursday. ReoPro...
BioCentury | Mar 29, 2010
Clinical News

Plavix clopidogrel regulatory update

...from Medicure Inc. (TSX:MPH, Winnipeg, Manitoba), Iroko Pharmaceuticals LLC (Philadelphia, Pa.) and Merck; and ReoPro abciximab...
BioCentury | Mar 29, 2010
Clinical News

ReoPro abciximab regulatory update

...from Medicure Inc. (TSX:MPH, Winnipeg, Manitoba), Iroko Pharmaceuticals LLC (Philadelphia, Pa.) and Merck; and ReoPro abciximab...
...Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: ReoPro abciximab...
BioCentury | Mar 29, 2010
Clinical News

Aggrastat tirofiban regulatory update

...Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.); Aggrastat tirofiban from Medicure, Iroko and Merck; and ReoPro abciximab...
Items per page:
1 - 10 of 272